Egyptian national HCV treatment program (National program)

green

Egyptian national HCV treatment program (National program)

Virus targets
Hepatitis B
Type
Operational research
Testing and treatment implementation
Setting
National
Phase
Active
Health outcomes
Incidence
Mortality
WHO region
Eastern Mediterranean Region
Target goal
Country
Egypt
Key interventions
Blood safety
Hepatitis B Vaccination
Injection safety and infection control
Strategic data analysis
Screening and diagnosis
Treatment (direct or referral)
Target population
Adolescents (10 - 19 years of age)
Adults (> 19 years of age)
Household contact(s)
Incarcerated populations (current and former)
Occupations with possible exposure
Sexual contact(s)
Performance target
Care cascade: Evidence of current infection
Care cascade: HCV diagnosis
Care cascade: HCV testing
Care cascade: HCV treatment
Care cascade: Referred for treatment
If you would like to have a program page for your program, please create an account and submit program information here

Health outcomes additional info

Identifcation and treatment of 90% of HCV infection by 2020

Summary and objectives

The program started in 2006. The National Committee for Control of Viral Hepatitis (NCCVH) started setting-up specialized viral hepatitis treatment centres, initially with one centre for interferon therapy of hepatitis C in 2006. By 2013, there were 26 specialized centres where patients with HCV were evaluated and treated with pegylated interferon and ribavirin. In 2014, direct antivirals were introduced, and there was a rapid treatment uptake in 2015-2016, where till end of 2018, 2.4 Million patients with HCV were treated with DAAs. • The current National population screening program will continue till the end of 2020, whereby all adults and children above the age of 12 would be screened for HCV antibodies, and all infected persons will be treated for free, fully funded by the state. So far, 52 Million adults and children above the age of 15 were screened, and 2.2 Million patients seropositive for HCV have been identiNed, evaluated, and are currently being treatred. • The NCCVH estimates that by end of 2020, 4.5 million patients would have been identiNed and treated. However, the project will be continuous, and the specialized centres will continue treatment of unidentiNed HCV patients, management of HBV infected patients, and follow-up and care for patients with liver cirrhosis Additional information

Last updated